Fluocinolone Acetonide Patent Expiration
Fluocinolone Acetonide is Used for managing chronic non-infectious uveitis affecting the posterior segment of the eye. It was first introduced by Medimetriks Pharmaceuticals Inc
Fluocinolone Acetonide Patents
Given below is the list of patents protecting Fluocinolone Acetonide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iluvien | US9849027 | Ocular implantation device | Nov 07, 2028 | Alimera Sciences Inc |
| Yutiq | US7998108 | Injector apparatus and method of use | Jan 12, 2028 | Alimera Sciences Inc |
| Iluvien | US8871241 | Injectable sustained release delivery devices | Aug 12, 2027 | Alimera Sciences Inc |
| Yutiq | US8871241 | Injectable sustained release delivery devices | Aug 12, 2027 | Alimera Sciences Inc |
| Iluvien | US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Yutiq | US6375972 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Yutiq | US8574613 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Yutiq | US8574659 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Yutiq | US9192579 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Yutiq | US9849085 | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Apr 26, 2020
(Expired) | Alimera Sciences Inc |
| Iluvien | US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun 27, 2019
(Expired) | Alimera Sciences Inc |
| Yutiq | US8252307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Jun 27, 2019
(Expired) | Alimera Sciences Inc |
| Iluvien | US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Alimera Sciences Inc |
| Iluvien | US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Alimera Sciences Inc |
| Retisert | US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Bausch And Lomb |
| Retisert | US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Bausch And Lomb |
| Yutiq | US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Alimera Sciences Inc |
| Yutiq | US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar 22, 2019
(Expired) | Alimera Sciences Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Fluocinolone Acetonide's patents.
Latest Legal Activities on Fluocinolone Acetonide's Patents
Given below is the list recent legal activities going on the following patents of Fluocinolone Acetonide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 01 Jan, 2024 | US9192579 |
| Maintenance Fee Reminder Mailed Critical
| 17 Jul, 2023 | US9192579 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Feb, 2023 | US7998108 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 07 Apr, 2022 | US7998108 |
| Expire Patent Critical
| 31 Jan, 2022 | US9849085 |
| Expire Patent Critical
| 13 Dec, 2021 | US8574613 |
| Expire Patent Critical
| 13 Dec, 2021 | US8574659 |
| Maintenance Fee Reminder Mailed Critical
| 16 Aug, 2021 | US9849085 |
| Maintenance Fee Reminder Mailed Critical
| 28 Jun, 2021 | US8574613 |
| Maintenance Fee Reminder Mailed Critical
| 28 Jun, 2021 | US8574659 |
Fluocinolone Acetonide's Family Patents
